November 2013

SillaJen to acquire Jennerex

Wednesday, November 27, 2013

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

[Read More]

Cincinnati area hospitals, universities form collaborative IRB

Wednesday, November 27, 2013

A group of hospitals and research institutions across Cincinnati and Northern Kentucky has formed a collaborative Institutional Review Board (IRB) agreement that will allow any of the six participating sites to serve as the IRB of record for research conducted across multiple participating study sites.

[Read More]

Genomic Health, Almac collaborate on test to predict chemotherapy benefits

Wednesday, November 27, 2013

Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer.  Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score. 

[Read More]

Nicox acquires Eupharmed

Wednesday, November 27, 2013

Nicox, an international pharmaceutical company focused on the ophthalmic market, has acquired Eupharmed, a privately-held Italian ophthalmic company, for $4.8 million in newly issued Nicox shares, plus milestones of up to $3.3 million. The acquisition provides Nicox with an established sales and marketing platform in Italy and a broad portfolio of eye care products. Eupharmed had sales of $4.9 million in 2012 and is expected to see full-year sales of approximately $5.3 million in 2013.

[Read More]

Joseph L. Herring, Neil M. Kurtz elected to Team Health Holdings board of directors

Tuesday, November 26, 2013

Team Health Holdings, a provider of outsourced physician staffing solutions for hospitals, has announced that Joseph L. Herring and Neil M. Kurtz, M.D., were elected to the company’s board of directors. As chairman of the board and CEO of Covance, Herring leads one of the largest public CROs in the world, managing $2.5 billion in revenue and 12,000 employees in 65 countries. As president and CEO of Golden Living, a privately-held skilled nursing, hospice, home healthcare and institutional pharmacy company with more than 300 locations nationwide, Kurtz leads the largest company of its kind in the industry, managing approximately $3 billion in revenue and 43,000 employees.

[Read More]

Boehringer Ingelheim planning two global trials of Pradaxa

Tuesday, November 26, 2013

Boehringer Ingelheim Pharmaceuticals plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI (Randomized Evaluation of Dual Therapy with Dabigatran v. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting), is designed to evaluate the efficacy and safety of PRADAXA in patients with non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stent placement. The second of the new trials, RE-SPECT ESUS(TM) (Randomized Evaluation in Secondary stroke Prevention Comparing the Thrombin inhibitor dabigatran etexilate v. ASA in Embolic Stroke of Undetermined Source), is designed to evaluate the efficacy and safety of PRADAXA as a secondary stroke prevention therapy in patients who have suffered an embolic stroke of undetermined source (ESUS). Embolic strokes occur when a blood clot forms somewhere in the body and travels through the bloodstream to the brain.

[Read More]